β‐Adrenergic modulation of skeletal muscle contraction: key role of excitation–contraction coupling
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Our aim is to describe the acute effects of catecholamines/β‐adrenergic agonists on contraction of non‐fatigued skeletal muscle in animals and humans, and explain the mechanisms involved. Adrenaline/β‐agonists (0.1–30 μ m) generally augment peak force across animal species (positive inotropic effect) and abbreviate relaxation of slow‐twitch muscles (positive lusitropic effect). A peak force reduction also occurs in slow‐twitch muscles in some conditions. β 2‐Adrenoceptor stimulation activates distinct cyclic AMP‐dependent protein kinases to phosphorylate multiple target proteins. β‐Agonists modulate sarcolemmal processes (increased resting membrane potential and action potential amplitude) via enhanced Na+–K+ pump and Na+–K+–2Cl− cotransporter function, but this does not increase force. Myofibrillar Ca 2+ sensitivity and maximum Ca 2+‐activated force are unchanged. All force potentiation involves amplified myoplasmic Ca 2+ transients consequent to increased Ca 2+ release from sarcoplasmic reticulum (SR). This unequivocally requires phosphorylation of SR Ca 2+ release channels/ryanodine receptors (RyR1) which sensitize the Ca 2+‐induced Ca 2+ release mechanism. Enhanced trans‐sarcolemmal Ca 2+ influx through phosphorylated voltage‐activated Ca 2+ channels contributes to force potentiation in diaphragm and amphibian muscle, but not mammalian limb muscle. Phosphorylation of phospholamban increases SR Ca 2+ pump activity in slow‐twitch fibres but does not augment force; this process accelerates relaxation and may depress force. Greater Ca 2+ loading of SR may assist force potentiation in fast‐twitch muscle. Some human studies show no significant force potentiation which appears to be related to the β‐agonist concentration used. Indeed high‐dose β‐agonists (∼0.1 μ m) enhance SR Ca 2+‐release rates, maximum voluntary contraction strength and peak Wingate power in trained humans. The combined findings can explain how adrenaline/β‐agonists influence muscle performance during exercise/stress in humans. image
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and Regulation of Voltage-Gated Ca 2+ Channels
Catterall, W. A. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.521 · Cited by 2,344
Role of β-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease
Lynch, G. S., & Ryall, J. G. (2008) · Physiological Reviews · doi:10.1152/physrev.00028.2007 · Cited by 410
Cited by
Egan, B., & Sharples, A. P. (2023) · Physiological Reviews · doi:10.1152/physrev.00054.2021 · Cited by 278
Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects
Heuberger, J. A. A. C., & Cohen, A. F. (2019) · Sports Medicine · doi:10.1007/s40279-018-1014-1 · Cited by 108
Regulation of muscle potassium: exercise performance, fatigue and health implications
Lindinger, M. I., & Cairns, S. P. (2021) · European Journal of Applied Physiology · doi:10.1007/s00421-020-04546-8 · Cited by 78
Self-citationSpecific ATPases drive compartmentalized glycogen utilization in rat skeletal muscle
Nielsen, J., Dubillot, P., Stausholm, M.-L. H., & Ørtenblad, N. (2022) · Journal of General Physiology · doi:10.1085/jgp.202113071 · Cited by 18
Combinatory in vitro effects of the β2-agonists salbutamol and formoterol in skeletal muscle cells
Piribauer, M., Jiang, L., Kostov, T., Parr, M., Steidel, S., Bizjak, D. A., Steinacker, J. M., & Diel, P. (2023) · Toxicology Letters · doi:10.1016/j.toxlet.2023.02.007 · Cited by 10
Metadata
- Authors
- Cairns, S. P., & Borrani, F.
- Venue
- The Journal of Physiology
- Publisher
- Wiley
- Published
- 2015-10-29
- Volume
- 593
- Issue
- 21
- Pages
- 4713-4727
- ISSN
- 0022-3751 (ISSN-L)
- 1469-7793
- OpenAlex
- W2133621497
- Cited by
- 97
- References
- 2
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.